The partnership with Cancer Pledge is likely to be viewed positively by investors and the public, reflecting well on NeoGenomics' corporate image and potentially attracting talent who value corporate responsibility. This could lead to a positive short-term impact on the stock as the market reacts to the company's commitment to employee welfare and social responsibility.